结节边缘区淋巴瘤的回顾性特征分析
该研究回顾性分析了187例结节边缘区淋巴瘤(NMZL)患者的基线特征、生存结局和时间事件数据。五年总生存率为91%(95%CI 87-95),幸存者中位随访71个月。初始观察是常见合理策略,五年仍未治疗概率为25%(95%CI 19-33),初始观察者至活动治疗的中位时间为72个月。
要点
- 五年总生存率为91%(95%CI 87-95),幸存者中位随访71个月。
- 初始观察者五年仍未治疗概率为25%(95%CI 19-33),至活动治疗中位时间72个月。
- 接受至少一次活动治疗者60个月时需第二次活动治疗的累积发生率为37%。
核心结论
- NMZL通常表现为惰性淋巴瘤,初始观察常是合理策略。
研究设计与样本
- 回顾性分析连续187例NMZL患者,描述基线特征、生存结局和时间事件数据。
主要发现
- 五年总生存率为91%(95%CI 87-95),幸存者中位随访71个月(范围8-253)。
- 139例患者在任何时间点接受了活动治疗;从未治疗幸存者的中位随访时间为56个月(范围13-253)。
- 五年仍未治疗的概率为25%(95%CI 19-33)。
- 初始观察者至活动治疗的中位时间为72个月(95%CI 49-未达到)。
- 接受至少一次活动治疗者60个月时需第二次活动治疗的累积发生率为37%;10年时转化为大B细胞淋巴瘤的累积发生率为15%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has historically been difficult to define, though is now formally recognized by the World Health Organization Classification. To better characterize the clinical outcomes of patients with NMZL, we reviewed a sequential cohort of 187 patients with NMZL to describe baseline characteristics, survival outcomes, and time-to-event data. Initial management strategies were classified into five categories: observation, radiation, anti-CD20 monoclonal antibody therapy, chemoimmunotherapy, or other. Baseline Follicular Lymphoma International Prognostic Index scores were calculated to evaluate prognosis. A total of 187 patients were analyzed. The five-year overall survival was 91% (95% confidence interval [CI], 87-95), with a median follow-up time of 71 months (range, 8-253) among survivors. A total of 139 patients received active treatment at any point, with a median follow-up time of 56 months (range, 13-253) among survivors who were never treated. The probability of remaining untreated at five years was 25% (95% CI, 19-33). For those initially observed, the median time to active treatment was 72 months (95% CI, 49-not reached). For those who received at least one active treatment, the cumulative incidence of receiving a second active treatment at 60 months was 37%. Transformation to large B-cell lymphoma was rare, with a cumulative incidence of 15% at 10 years. In summary, our series is a large cohort of uniformly diagnosed NMZL with detailed analyses of survival and time to event analyses. We showed that NMZL commonly presents as an indolent lymphoma for which initial observation is often a reasonable strategy.
引用
- Stuver R, Drill E, Qualls D, et al. Retrospective characterization of nodal marginal zone lymphoma. Blood Adv. 2023. PMID: 37307213. doi:10.1182/bloodadvances.2022009587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。